Do Urate Targets Influence CV Risk?
-
By
January 30, 2026
-
3 min
A recent study involving over 109,000 adults with newly diagnosed gout found that only 27% achieved the recommended serum urate target of less than 6 mg/dL within 12 months of starting urate-lowering treatment (ULT). Achieving this target was linked to a 9% reduction in the relative risk of major adverse cardiovascular events (MACE), particularly in patients with high cardiovascular risk. Notably, achieving even lower urate levels under 5 mg/dL correlated with a 23% risk reduction for MACE, highlighting the significance of targeted treatment in managing gout and its cardiovascular complications.
1. 27% of gout patients reached serum urate target < 6 mg/dL in 12 months. 2. Achieving this target lowered MACE risk by 9%. 3. Serum urate levels under 5 mg/dL reduced MACE risk by 23%. 4. Allopurinol was prescribed to nearly all patients. 5. Study involved 109,504 adults, mean age 63. 6. Follow-up averaged 3.5 years, with a 14% MACE occurrence. 7. Potential bias from observational design noted. 8. Treat-to-target approach linked with fewer gout flares.
Listen Tab content
